Microbix Biosystems Past Earnings Performance
Past criteria checks 2/6
Microbix Biosystems has been growing earnings at an average annual rate of 50%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 10.9% per year. Microbix Biosystems's return on equity is 13.6%, and it has net margins of 16.6%.
Key information
50.0%
Earnings growth rate
53.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 10.9% |
| Return on equity | 13.6% |
| Net Margin | 16.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Microbix Biosystems makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 22 | 4 | 9 | 2 |
| 30 Sep 23 | 17 | 0 | 8 | 2 |
| 30 Jun 23 | 17 | -3 | 8 | 2 |
| 31 Mar 23 | 16 | -1 | 7 | 2 |
| 31 Dec 22 | 17 | 0 | 7 | 2 |
| 30 Sep 22 | 19 | 2 | 7 | 2 |
| 30 Jun 22 | 20 | 3 | 6 | 2 |
| 31 Mar 22 | 21 | 4 | 6 | 2 |
| 31 Dec 21 | 20 | 4 | 6 | 1 |
| 30 Sep 21 | 19 | 3 | 5 | 1 |
| 30 Jun 21 | 16 | -3 | 5 | 1 |
| 31 Mar 21 | 13 | -4 | 5 | 1 |
| 31 Dec 20 | 12 | -6 | 4 | 1 |
| 30 Sep 20 | 11 | -6 | 4 | 1 |
| 30 Jun 20 | 11 | -1 | 4 | 1 |
| 31 Mar 20 | 12 | -1 | 4 | 1 |
| 31 Dec 19 | 13 | 0 | 5 | 1 |
| 30 Sep 19 | 13 | 0 | 4 | 1 |
| 30 Jun 19 | 13 | -8 | 4 | 1 |
| 31 Mar 19 | 13 | -8 | 4 | 1 |
| 31 Dec 18 | 12 | -9 | 4 | 1 |
| 30 Sep 18 | 13 | -9 | 4 | 1 |
| 30 Jun 18 | 12 | -1 | 4 | 1 |
| 31 Mar 18 | 11 | -1 | 5 | 1 |
| 31 Dec 17 | 11 | -1 | 4 | 1 |
| 30 Sep 17 | 10 | -4 | 4 | 1 |
| 30 Jun 17 | 11 | -2 | 4 | 1 |
| 31 Mar 17 | 10 | -2 | 4 | 1 |
| 31 Dec 16 | 10 | -2 | 4 | 1 |
| 30 Sep 16 | 10 | 1 | 4 | 0 |
| 30 Jun 16 | 8 | 0 | 3 | 1 |
| 31 Mar 16 | 8 | 0 | 3 | 1 |
| 31 Dec 15 | 8 | 0 | 3 | 1 |
| 30 Sep 15 | 9 | 1 | 3 | 1 |
| 30 Jun 15 | 9 | 0 | 4 | 1 |
| 31 Mar 15 | 9 | 0 | 3 | 1 |
| 31 Dec 14 | 8 | 0 | 3 | 1 |
| 30 Sep 14 | 8 | 0 | 3 | 1 |
| 30 Jun 14 | 9 | 1 | 2 | 0 |
| 31 Mar 14 | 8 | 1 | 3 | 0 |
| 31 Dec 13 | 9 | 1 | 3 | 0 |
| 30 Sep 13 | 8 | 0 | 3 | 0 |
| 30 Jun 13 | 7 | -1 | 3 | 1 |
Quality Earnings: MBXB.F has a high level of non-cash earnings.
Growing Profit Margin: MBXB.F became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MBXB.F has become profitable over the past 5 years, growing earnings by 50% per year.
Accelerating Growth: MBXB.F has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: MBXB.F has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: MBXB.F's Return on Equity (13.6%) is considered low.